drugset / Trial / NCT01830101
A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators hope to improve overall median survival of patients with recurrent Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five treatments of re-irradiation.
Timeline
- Start
- 2014-02
- Primary completion
- 2015-05
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Temozolomide | Small molecule | — | — |